These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 6794530)
1. [Clinical pharmacology of prazosin in arterial hypertension with chronic renal insufficiency]. Chaignon M; Le Roux E; Aubert P; Lucsko M; Flouvat B; Guédon J Arch Mal Coeur Vaiss; 1981 Jun; 74 Spec No():71-7. PubMed ID: 6794530 [TBL] [Abstract][Full Text] [Related]
2. [Effect of the alpha 1-receptor blocker prazosin and the beta 1-receptor blocker acebutolol and their combination on blood pressure and pressure rate product. Ergometric studies of hypertensive patients]. Franz IW Z Kardiol; 1984 Jan; 73(1):21-8. PubMed ID: 6367245 [TBL] [Abstract][Full Text] [Related]
3. An evaluation of the efficacy and safety of doxazosin in the treatment of hypertension associated with renal insufficiency. Anderton JL; Notghi A J Hum Hypertens; 1990 Oct; 4 Suppl 3():52-7. PubMed ID: 2148196 [TBL] [Abstract][Full Text] [Related]
4. Prazosin in hypertension. Part II. Effects of the initial dose. Turner AS; Watson OF; Brocklehurst JE N Z Med J; 1977 Sep; 86(596):286-9. PubMed ID: 343006 [TBL] [Abstract][Full Text] [Related]
5. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548 [TBL] [Abstract][Full Text] [Related]
6. Effects of prazosin in the control of blood pressure in hypertensive dialysis patients. Harter HR; Delmez JA J Cardiovasc Pharmacol; 1979; 1(6 Suppl):S43-55. PubMed ID: 94639 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy of prazosin in severe cardiac insufficiency]. Timio M; Gentili S; Schiaroli M; Ronconi M G Ital Cardiol; 1979; 9(12):1371-7. PubMed ID: 549785 [TBL] [Abstract][Full Text] [Related]
9. Effect of prazosin on blood lipids and on thyroid function in hypertensive patients. Velasco M; Silva H; Morillo J; Pellicer R; Urbina-Quintana A; Hernández-Pieretti O J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S225-7. PubMed ID: 6177961 [TBL] [Abstract][Full Text] [Related]
10. [Immediate and long-term effects of prazosin on hemodynamics in chronic cardiac insufficiency]. Champoud O; Brunhes G; Cribier A; Pasquis P; Letac B Arch Mal Coeur Vaiss; 1982 Jun; 75(6):687-93. PubMed ID: 6810798 [TBL] [Abstract][Full Text] [Related]
11. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic congestive failure with vasodilators (acute trial with prazosin and erythrityl tetranitrate)]. Tomov I; Kaloianova A; Terzieva L; Nikolov G; Elenkova A Vutr Boles; 1982; 21(6):45-50. PubMed ID: 6761964 [TBL] [Abstract][Full Text] [Related]
13. Clonidine and prazosin in the treatment of hypertensive outpatients--a preliminary study. González-Gómez A; Díaz Novás J; Gamio Capestany F; Rodríguez de la Vega A; García-Barreto D Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):524-8. PubMed ID: 6642791 [TBL] [Abstract][Full Text] [Related]
15. Prazosin GITS vs sustained release nifedipine in patients with hypertension and abnormal lipid profile: a randomized, controlled, multicenter study. Madras Hypertension Study Group. Misra KP; Joglekar SJ; Mukherjee S; Nanivadekar AS J Assoc Physicians India; 1998; Suppl 1():30-40. PubMed ID: 11233385 [TBL] [Abstract][Full Text] [Related]
16. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study. Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T; Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719 [TBL] [Abstract][Full Text] [Related]
17. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Siu YP; Leung KT; Tong MK; Kwan TH Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385 [TBL] [Abstract][Full Text] [Related]
18. Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure. Portaluppi F; Vergnani L; Manfredini R; degli Uberti EC; Fersini C Am J Hypertens; 1995 Jul; 8(7):719-26. PubMed ID: 7546498 [TBL] [Abstract][Full Text] [Related]
19. Chronic alpha1-adrenergic blockade improves hypertension and renal injury in L-NAME and low-renin L-NAME-DOCA hypertensive rats. Wangensteen R; O'Valle F; Del Moral R; Vargas F; Osuna A Med Sci Monit; 2002 Sep; 8(9):BR378-84. PubMed ID: 12221376 [TBL] [Abstract][Full Text] [Related]
20. Prazosin-induced haemodynamic modification in human hypertension. Evidence from strain-gauge plethysmography. Part II. Romano S; Gizdulich P; Scarpelli PT Methods Find Exp Clin Pharmacol; 1981; 3(1):13-5. PubMed ID: 7230971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]